150
Participants
Start Date
January 22, 2021
Primary Completion Date
January 22, 2030
Study Completion Date
January 22, 2030
Molecular testing for all participants.
Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.
Germline Testing
Germline testing will be done on prospectively identified patients and in retrospectively identified patients who are still alive.
Survey
Survey will be administered on prospectively identified patients and in retrospectively identified patients who are still alive. Survey will be administered in person or via telephone. The survey in the language of the participants choice (English or Spanish) on sociodemographic information, current and/or prior PPI (proton pump inhibitor), H2 blocker, antibiotic, tobacco, alcohol, and recreational drug use. Questionnaire will include other risk factors for gastric adenocarcinoma such as certain dietary constituents (high salt diet, high consumption of processed meat, etc.) and occupational exposures.
RECRUITING
Mays Cancer Center, UT Health San Antonio, San Antonio
IIMS-UT Health San Antonio
UNKNOWN
National Center for Advancing Translational Sciences (NCATS)
NIH
The University of Texas Health Science Center at San Antonio
OTHER